The Pharmaletter

One To Watch

Helicore Biopharma

A biopharma company developing first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions.

Helicore emerged from stealth mode in January 2025 with $65 million in Series A financing. The round was co-led by founding investor Versant Ventures and by OrbiMed, with participation from Longitude Capital and Wellington Management.

The company's most advanced asset, HCR-188, is a clinical stage monoclonal antibody (mAb) designed to bind GIP. The company’s portfolio includes GIP antibody conjugates, including GLP-1 and other combinations, designed to address specific obesity subpopulations.

Want to Update your Company's Profile?


Latest Helicore Biopharma News

More Helicore Biopharma news >